International Journal of Hematology and Oncology 2019, Vol 29, Num 3 Page(s): 030-035
Cardioprotective Effect of Clarithromycin on Doxorubicin-Induced Cardiac Toxicity in Rats

Mustafa DOGAN1, Fatih FIRINCI1, Yasemin I. BALCI1, Dolunay GURSES1, Aziz POLAT1, Ozmert MA OZDEMIR1, Yasar ENLI2, Metin AKBULUT3, Barbaros SAHIN4

1Pamukkale University Faculty of Medicine, Department of Pediatrics, Denizli, TURKEY
2Pamukkale University Faculty of Medicine, Department of Biochemistry, Denizli, TURKEY
3Pamukkale University Faculty of Medicine, Department of Pathology, Denizli, TURKEY
4Pamukkale University, Faculty of Medicine, Department of Multidicipliner Laboratory, Denizli, TURKEY

Keywords: Doxorubicin, Cardiotoxity, Clarithromycin, Rat
Doxorubicin is an anthracycline group antibiotic and has long been used as an antineoplastic agent. The most important side effect that limits the usage of doxorubicin is cardiotoxicity, which is observed at cumulative doses. We investigated the protective effect of clarithromycin that is known to have antioxidant and anti-inflammatory effects against Doxorubicin related cardiotoxicity. The aim of our study was to evaluate the effects of clarithromycin in the antioxidant enzyme status and myocardium of doxorobucine-treated rats. A total of 28 adult, male Wistar rats (200-250 g) were divided into 4 groups. Group I was the control group, rats in group 2 were administered doxorubicin, rats in group 3 were administered clarithromycin, and rats in group 4 were administered Doxorubicin + Clarithromycin. Following the scarification of all rats, antioxidant (glutathione) and oxidant (malodialdehyde) levels were measured in the cardiac tissue. Additionally, the cardiac muscles were evaluated histopathologically via hematoxylin eosin staining. The antioxidant amount (glutathione) was significantly higher in the treatment group compared to the doxorubicin group (p= 0.025), whereas the amount of oxidant (malondialdehyde) was significantly lower (p= 0.022). The histopathological examination revealed significant cardiotoxicity in the Doxorubicin group and significant reduction in the cardiotoxicity in the Doxorubicin + Clarithromycin group. The results obtained in this study provide evidence for the usefulness of the clarithromycin as a cardioprotective agent.